Browsing: Filing

Eli LillyLLYfell 0.35% in premarket after reporting positive results from two further Phase 3 trials of retatrutide and confirming it will submit a biologics license application to the FDA in the first quarter of 2027. The drug targets three metabolic hormones, GLP-1, GIP and glucagon, against two for Lilly’s current Zepbound and one for Novo…